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Introduction: Giant cell arteritis is a vasculitis of large and middle-sized arteries that 
affects individuals older than 50 years. Although glucocorticoids remain the mainstay in 
the treatment of this vasculitis, other drugs are often required to achieve clinical 
remission and allow glucocorticoid discontinuation.   
Areas covered: The review summarizes the main biologic therapies used for the 
managements of GCA.    
Expert commentary: Although several biologic agents have been used in patients with 
GCA, the only biologic agent currently approved for this purpose is the recombinant 
humanized anti-IL-6 receptor antibody: tocilizumab. It has demonstrated efficacy to 
improve clinical symptoms, decrease the cumulative prednisone dose and reduce the 
frequency of relapses in clinical trials and real-life studies on patients with GCA. A trial 
showed that abatacept may be useful to maintain remission in GCA patients. An open-
label study suggested that ustekinumab could be useful for the treatment of patients with 
refractory GCA. However, further studies are required to confirm if both abatacept and 
ustekinumab are useful as an adjunctive therapy to reduce relapses or as a 
glucocorticoidsparing agent in GCA. Anakinra has been successfully used in a few 
patients with refractory GCA. In contrast, anti-tumor necrosis factor-α therapy yielded 
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1. Introduction  
Giant cell arteritis (GCA) is a granulomatous vasculitis that affects large and middle-
sized arteries. It occurs in people 50 years and older, being the most common vasculitis 
in elderly people from Europe and North America, in particular in those of 
Scandinavian background [1,2]. The highest incidence of GCA is observed in the 70-80 
age group [3]. 
The etiology of GCA is unknown. Infectious and other unidentified environmental 
factors in individuals genetically predisposed trigger a systemic inflammatory response 
leading to a dysregulation of the immune system involving Th1 and Th17 lymphocyte 
subpopulations with the overproduction of pro-inflammatory cytokines such as 
interleukin (IL)-1, IL-6, IL-17, interferon (IFN)-γ and, to a lesser extent, tumor necrosis 
factor (TNF)-α [1,2,4]. 
Histopathological changes in blood vessels from patients with GCA include the 
presence of a mononuclear inflammatory infiltrate that can affect all layers of the 
arterial wall, with or without multinucleated giant cells along with disruption of the 
internal elastic lamina and vascular remodeling signs with destruction of the arterial 
wall, intimal hyperplasia and neoangiogenesis. Arterial damage leads to partial or 
complete obstruction of local arterial blood flow with the corresponding clinical 
manifestations of ischemia [4,5].  
Typical cranial symptoms include an abrupt onset of headache, scalp tenderness, jaw 









involvement of branches derived of the external carotid artery [2,6]. GCA patients may 
suffer visual manifestations, such as amaurosis fugax or permanent visual loss, which 
are generally due to involvement of the posterior ciliary arteries that are branches of the 
internal carotid artery [7]. Patients with GCA have an increased risk of developing 
aneurysms and dissection over the course of the disease, especially in the thoracic 
segment of the aorta [8,9]. In a recent study, structural damage in the aorta affected up 
to 33.3% of individuals after long term follow-up [10]. Once aortic structural damage 
occurs, dilatation increases over time, underlining the need for periodic evaluation [10].  
GCA patients often have polymyalgia rheumatica (PMR) features that may be occur 
before, simultaneously or after the diagnosis of GCA has been established [11]. A small 
proportion of patients with GCA may suffer strokes that affect more often the 
vertebrobasilar territory at early stages and the carotid branches during follow-up [12]. 
Additionally, patients with GCA often have non-specific clinical features, such as low-
grade fever, malaise, asthenia, and weight loss [13].  
A physical examination may disclose thickening, tenderness or reduced pulsation of the 
temporal arteries [14]. Pulse deficits, bruits or asymmetric arterial pressure 
measurements in any of the four limbs may also be observed in patients with 
extracranial large-vessel involvement [8]. 
Most patients have abnormality of acute phase reactants (erythrocyte sedimentation rate 
[ESR] and C reactive protein [CRP]) [15]. However, there is a small subgroup (~5%) 
with normal inflammatory markers, who are more likely to be overlooked, reason why 
they may be at increased risk of visual loss. Anemia, high platelet count and elevation 
of hepatic function tests may also be frequently observed [2,15]. 
Patients with GCA often experience relapses that present with manifestations of the 









symptoms. Relapses are generally associated with elevation of acute phase reactants 
[16]. They constitute a challenge for the clinician since they may occur in almost 50% 
of the patients when glucocorticoid therapy is tapered [17]. 
Although a temporal artery biopsy showing the typical inflammatory infiltrate has been 
considered the gold-standard tool for the diagnosis [5], color duplex ultrasonography 
showing arterial wall edema (the “halo sign”) has been proposed as alternative to 
temporal artery biopsy in patients presenting with the typical cranial pattern of GCA 
[6,18]. Other imaging techniques, such as the magnetic resonance, computed 
tomography (CT)-angiography, and [18F]-fluorodeoxyglucose (FDG)-positron emission 
tomography (PET/CT) are useful to diagnose patients with predominant extracranial 
manifestations [19,20]. Interestingly, in these cases with predominant large-vessel 
vasculitis without cranial involvement a temporal artery biopsy often yields negative 
results [21].  
 
2.  Areas covered 
Glucocorticoids are the cornerstone of treatment of GCA [4,5]. Conventional 
immunosuppressive drugs, mainly methotrexate (MTX), have been used as 
glucocorticoid-sparing agents and to reduce the frequency of relapses. However, results 
in terms of efficacy have not been well established [22].  
A recent review summarized the most common conventional immunosuppressive drugs 
used in patients with GCA [23]. According to data shown in this review, MTX is still 
the most commonly used conventional immunosuppressive drug for the management of 
refractory GCA. However, the efficacy of this drug in GCA is modest [23]. Also, the 
experience with other conventional immunosuppressive drugs in GCA patients is small 









In the present review, we have focused on the use of biologic agents in GCA. 
Information on the recently approved use of the anti-IL-6 receptor tocilizumab is 
discussed in depth. The potential efficacy of other biologic agents is also discussed.  
 
2.1. Role of the biologic agents in the management of GCA 
2 1.1. Anti-tumor necrosis factor (TNF) therapy: Disappointing results  
Anti-TNF-α agents proved efficacy in patients with inflammatory arthritis. In addition, 
there are some evidences that TNF-α could play a pathogenic role in this disease [24-
26]. Because of that, anti-TNF-α drugs were also tested in patients with GCA. However, 
the results turned out to be negative to maintain remission in newly diagnosed patients. 
Hoffman et al. conducted the most important study that consisted of a phase II study, 
randomized, double-blind, placebo-controlled trial to determine the efficacy of the 
chimeric monoclonal antibody-infliximab in GCA patients with new onset disease [27]. 
The study included 44 patients that had obtained resolution of symptoms and 
normalization of ESR following treatment with 40-60 mg/day of 
prednisone/prednisolone. For the inclusion in the study patients required to have been in 
remission of the disease for at least 1 week before randomization [27]. Patients received 
an initial dose of 40-60 mg/prednisone/day and they were randomized to receive either 
placebo (n=16) or infliximab 5 mg/kg/infusion (n=28) at baseline (week 0) and at weeks 
2, 6, 14, 22, 30, 38 and 46. However, there were no differences between both groups 
after 22 weeks of follow-up. Infliximab-did not yield significant reduction in the 
cumulative doses of prednisone or in the number of patients free of relapses [27]. With 
respect to the efficacy of other TNF-antagonists the information is scarce and roughly 
negative in terms of efficacy. A study using the human anti-TNF monoclonal antibody 









efficacy to reach remission with a dose of less than 0.1 mg/kg of prednisone at 6 
months. In addition, those who received adalimumab had more infections [28]. 
Information on another TNF-antagonist, etanercept, is also limited to a pilot study that 
did not confirm efficacy in patients with GCA [29].   
 
2.1.2. Interleukin (IL)-6 inhibitors: Tocilizumab approved for the management of 
GCA  
IL-6 is a pivotal proinflammatory cytokine that is produced in the inflamed arteries of 
patients with GCA [30]. It is also expressed in the monocytes of these patients [31]. 
GCA patients have increased IL-6 serum levels [32,33]. IL-6 concentration is closely 
related to disease activity and the CRP level. Persistence of high serum IL-6 levels 
suggests the presence of disease activity in glucocorticoid-treated patients with GCA 
[33]. Dasgupta and Panayi highlighted for first time that the use of glucocorticoids led 
to a rapid reduction of the levels of IL-6 in patients with GCA [34]. Since such a 
reduction of IL-6 serum levels was associated with a reduction in disease activity, the 
blockade of IL-6 was considered as a plausible therapeutic option in GCA [35]. Over 
the last ten years several case reports or small series highlighted the efficacy of the anti-
IL-6 receptor (tocilizumab) in both newly diagnosed and relapsing patients with GCA 
patients with GCA [36,37]. In a retrospective, open-label, study, we observed that 
tocilizumab was useful in 22 patients with refractory and relapsing GCA [38]. All the 
patients from our series had been treated with high dose prednisone and 19 of them had 
also received conventional immunosuppressive drugs and/or biologic agents. The most 
common reason for using intravenous tocilizumab (8 mg/kg/ month) in our series was 
the absence of efficacy following glucocorticoid and immunosuppressive therapy [38]. 









correlated with a statistically significant reduction of CRP and ESR [38]. Prednisone 
tapering was successfully achieved in 20 of the 22 patients [38]. Similar beneficial 
effects were observed in another retrospective multicenter study showed beneficial 
effect of tocilizumab in 28 of 34 GCA patients [39].  
Two placebo-controlled trials have confirmed the efficacy of tocilizumab in patients 
with GCA [40,41]. The first of them was a phase 2 study in which the assessor judging 
clinical response was not blinded to the laboratory findings, being allowed to make 
changes in the treatment during the follow-up based on laboratory alterations [40]. It 
included 23 newly diagnosed and 7 with relapsing patients with GCA who were 
randomized to receive intravenous anti-IL-6 receptor tocilizumab at a dose of 8 mg/kg 
every 4 weeks plus prednisolone (n=20 patients) or placebo infusion every 4 weeks plus 
prednisolone (n=10). The primary endpoint was the percentage of patients who 
achieved complete remission at a prednisolone dose of 0.1 mg/kg/day at week 12. At 
that time, 17 of the 20 tocilizumab-treated GCA patients obtained complete remission 
whereas it only occurred in 4 of the 10 placebo-treated patients [40]. Tocilizumab use 
allowed performing a rapid glucocorticoid tapering followed by discontinuation after 36 
weeks of from the onset of tocilizumab. The cumulative prednisolone dose at 52 weeks 
was significantly lower in the tocilizumab group (43 mg/kg) than in the placebo group 
(110 mg/kg). Relapse-free survival at 52 weeks was also significantly higher in the 
tocilizumab-treated patients (85%) than in those who received placebo (20%) [40]. A 
single patient undergoing tocilizumab suffered a relapse. However, relapses occurred 
once that tocilizumab was discontinued [40]. Regarding safety, seven (35%) patients in 










This study confirmed the efficacy of tocilizumab to induce remission, prevent relapses, 
and decrease the cumulative glucocorticoid dose. However, from our point of view, the 
fact that CRP and the clinical response were considered together as a combined final 
endpoint could have overestimated the actual number of remissions, because 
tocilizumab is very effective to decrease the levels of CRP [40]. 
The strongest evidence of the efficacy of the anti-IL-6 receptor monoclonal antibody-
tocilizumab comes from the tocilizumab in GCA (GiACTA) trial [41]. The study 
included 251 patients from 14 countries and 76 sites, 61 of them from Europe and 15 
from North America. The diagnosis of newly diagnosed cases and relapsing GCA 
patients was based on the results of a positive temporal-artery biopsy showing features 
of GCA or through imaging techniques showing large-vessel vasculitis and disease 
activity (cranial symptoms or PMR with an increase of acute-phase reactants). The 
number of patients recruited was very similar in both groups (119 newly diagnosed and 
132 relapsing patients) [41].  Patients were included in one of the four following groups: 
a weekly dose of 162 mg of subcutaneous tocilizumab plus a 26-week prednisone taper, 
a dose of f 162 mg of subcutaneous tocilizumab given every other week along with a 
26-week prednisone taper, a third group of weekly placebo-treated patients along with a 
26-week prednisone taper, and a fourth group of weekly placebo-treated plus a 52-week 
prednisone taper. 
Both groups of patients treated with tocilizumab achieved sustained remission more 
commonly than those placebo-treated at 52-week. Whereas 56% of the patients 
receiving subcutaneous tocilizumab every week and 53% of those treated with 
subcutaneous tocilizumab every other week achieved remission, only 14% and 18% of 
the patients treated with placebo plus 26-week prednisone taper or 52-week prednisone 









significance, patients who underwent tocilizumab therapy had less commonly relapse of 
the disease (23% and 26% in those treated with tocilizumab every week or every other 
week) than those included in the 26 and 52-week placebo arms (68% and 49%, 
respectively). The investigators from this phase 3 trial confirmed that tocilizumab use 
was associated with a powerful glucocorticoid-sparing effect [41]. This effect was 
stronger in those patients who had experienced relapses before randomization. Patients 
who received tocilizumab had less serious adverse events than those treated with 
placebo [41]. Taking together these positive findings the weekly use of subcutaneous 
tocilizumab was recently approved by the United States FDA and the European 
Commission for the treatment of GCA.  
Recent results from a real-world study of our group on 134 refractory GCA patients 
treated with tocilizumab support the conclusions of the GiACTA trial. We have 
observed a rapid and maintained clinical and laboratory improvement without 
differences in the GCA time course (greater than or less than 6 months), administration 
route (intravenous or subcutaneous) or prednisone dose at the time of the tocilizumab 
onset (≤ 15 mg/day or > 15 mg/day) [42]. Nevertheless, we believe that the GiACTA 
trial has several limitations [23]. In this regard, half of the patients had short disease 
duration since the inclusion in the study was made within the first six weeks after the 
disease diagnosis. A major point of potential concern is related to be the definition of 
remission, which was considered as the absence of relapse (flare) plus normalization of 
the CRP. Since tocilizumab yields a marked reduction of acute phase reactants CRP and 
ESR, it is difficult to determine whether the effect mediated by this agent leads to a true 
remission of this vasculitis without having histopathology or imaging exams supporting 
such an improvement [23]. Regarding this point, we and others have observed persistent 









asymptomatic with normal ESR and CRP [43]. Another potential limitation of the 
GiACTA trial was the scarce information on the effect of tocilizumab on visual loss, 
due to the small number of patients with unilateral or bilateral blindness at the time of 
inclusion. However, tocilizumab has been approved in patients with GCA and several 
open-label studies indicate that this biologic agent may also be useful for the 
management of refractory patients with other types of large vessel vasculitis. 
Tocilizumab therapy also yielded beneficial effects in patients with isolated aortitis and 
Takayasu´s arteritis, who were refractory to glucocorticoids and in many cases to other 
immunosuppressive agents [44,45].  
Other anti-IL-6 monoclonal antibody, different from tocilizumab, are currently under 
investigation in GCA. A phase-3 randomized, controlled, double-blind study using 
sirukumab, a fully human anti-IL-6 IgG1 antibody that blocks the IL-6 pathway a phase 
3 trial (ClinicalTrials.gov Identifier: NCT02531633) was initiated but it was cancelled. 
Also, sarilumab, another anti-IL-6 receptor agent, is under study for its potential use and 
safety in GCA (ClinicalTrials.gov Identifier: NCT03600805).  
 
2.1.3. Abatacept  
Some patients treated with the biologic agent ipilimumab for malignant melanoma have 
developed GCA [46]. Ipilimumab is a monoclonal antibody directed against cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) expressed on the surface of activated T 
cells [46]. The recombinantIg-CTLA-4 molecule abatacept, a fusion protein composed 
of the crystallizable fragment of a human IgG1 and the extracellular domain of CTLA-
4, binds to CD80/86 blocking its interaction with CD28, which decreases T cell 
activation. To determine safety and efficacy to maintain remission of the intravenous 









10 mg/kg intravenously of abatacept on days 1, 15, 29, and at week 8, together with 
prednisone. At week 12, 41 patients who had reached remission were blindly 
randomized to receive either monthly placebo intravenous infusions (n=21) or monthly 
intravenous abatacept (n=20). Patients included in both study arms performed a 
standardized tapering prednisone dose until discontinuation at week 28. The median 
duration of remission was also significantly longer in abatacept-treated patients (9.9 
months versus 3.9 months in those who received intravenous placebo). The primary 
outcome of the study, relapse-free survival at 12 months, was significantly more 
common in patients treated with intravenous abatacept (48%) than in those treated with 
placebo (31%) [47]. Abatacept-treated patients also had longer duration of remission 
than those who received placebo. There were no differences in side effects between 
abatacept and placebo-treated groups [47].   
Although these results look promising, some investigators have pointed out that due to 
the nonstandard design, in particular on glucocorticoid management, this study cannot 
be compared with the standard of care [48]. Moreover, another point that limits our 
ability to generalize the results of this study is the small number of patients assessed (n= 
41). Therefore, further studies encompassing larger number of patients are needed to 
confirm whether abatacept is useful as adjunctive treatment to reduce relapses or as a 
glucocorticoidsparing agent in patients with GCA. 
 
2.1.4. Ustekinumab 
IL-12 and IL-23 are two key cytokines involved in the anomalous Th1 and Th17 
response occurring in the pathogenesis of GCA. Ustekinumab is a monoclonal antibody 
that acts targeting both IL-12 and IL-23 pathways. It leads to a disruption of the Th1 









ustekinumab given at week 0, week 4 and week 16, a marked reduction of Th1 and 
Th17 cells and cytotoxic T lymphocytes at peripheral blood was observed compared to 
baseline in patients with refractory GCA [49]. A significant increase of Tregs was also 
observed [49].  
An open-label study showed efficacy of ustekinumab in 14 patients with long disease 
duration (median 30 months) GCA who were unable to taper glucocorticoids due to 
active GCA with a minimum of two relapses. Ustekinumab was prescribed at 90 mg 
subcutaneously at week 0, week 4 and then every 12 weeks (median 8 months) [50].    
Ustekinumab use was associated with a reduction of the glucocorticoid dose [50]. 
Glucocorticoids were successfully discontinued in 3 patients and in 8 patients 
ustekinumab allowed the discontinuation of the baseline immunosuppressive agents. 
Although there were not relapses while the patients were undergoing ustekinumab 
therapy, they were common once that ustekinumab was discontinued.  
An open label study to test the safety and efficacy of ustekinumab in patients with GCA 
is underway (estimated study completion date March 2020). 
 
 2.1.5. Anti-IL-1β agents 
Since the expression of IL-1β mRNA is increased in the temporal arteries of patients 
with biopsy-proven GCA, IL-1β antagonists have been proposed as potential agents to 
be used in the management of GCA. Among them, anakinra (IL-1Ra) was successfully 
used at a dose of 100 mg/day in three refractory GCA patients [51].  Because of that, a 
phase-III study is intended to be performed to assess the efficacy of this IL-1β 









Gevokizumab, a recombinant humanized anti-IL-1β antibody, is also under 
investigation for the management of GCA (European Clinical Trials Database Identifier 
2013–002778–38). 
 
2.1.6. Novel agents: JAK/STAT inhibitors 
A great number of cytokines that are immune relevant mediators use the Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathway to 
transduce intracellular signals [52]. Ligand binding of these immune mediators to their 
cell surface receptors leads to activation of associated JAKs. The activated JAKs 
increase their kinase activity, recruit, bind and activate STAT. The STAT molecules 
constitute hetero- or homo-dimers which translocate to the nucleus, inducing 
transcription and expression of target genes. Polymorphisms of JAK and STAT genes 
have been associated with autoimmune diseases [52].  
STAT-1 signaling regulates the activity of vascular dendritic cells, controlling T cell 
trafficking and retention of inflammatory T cells in the vascular lesions [53,54]. IFN-γ 
is the major inducer of STAT-1. In an experimental model in immunodeficient mice, in 
which animals were engrafted with human medium-sized arteries and then reconstituted 
with peripheral blood mononuclear cells from patients with biopsy-proven GCA, 
dexamethasone suppressed the innate immunity with inhibition of dendritic cell 
activation, IL-6 and IL-1β expression in the vascular lesions. However, dexamethasone 
spared adaptive immunity and left IFN-γ-producing Th1 unaffected [53]. The 
JAK/STAT-inhibitor tofacitinib, a kinase inhibitor for JAK1 and JAK3, prevented T 
cell accumulation in the vessel wall and suppressed IFN-γ production and signaling in a 
model of vascular inflammation in human arteries engrafted into immunodeficient mice 









Tofacitinib also led to a marked reduction of the blood levels of IFN-γ [53,54].   
Baricitinib is an inhibitor of 1 and JAK2 that inhibits Th17 (IL-6, IL23) and Th1 (IL-12, 
IFN-γ) pathways. In this way, a phase-II open-label pilot study with baricitinib is 
currently recruiting patients with relapsing GCA (NCT03026504) whose estimated 
primary completion results will be presented by June 2020. 
 
2.2. Conclusions  
GCA is the most common vasculitis in elderly people from Western countries. 
Glucocorticoids constitute the gold standard for the management of GCA. Although 
successful response is achieved in most patients, relapses are frequent when 
glucocorticoids are tapered and side effects are frequent as the result of prolonged use of 
glucocorticoids. For this reason, alternative therapies are often required in patients with 
GCA. Although MTX is the first agent used in patients with refractory GCA, the 
benefits associated with the use of this conventional immunosuppressive drug are mild.  
For this reason, novel biologic therapies that were previously used in inflammatory 
arthritis and other autoimmune disease have been tested for its efficacy in GCA. The 
first studies were conducted using anti-TNF-α agents. However, they yielded negative 
results. In contrast, the anti-IL-6 receptor tocilizumab has proved to be effective in the 
management of GCA. Tocilizumab appears to be especially useful in patients with 
refractory disease, allowing a reduction of the cumulative glucocorticoid dose and 
reducing the frequency of relapses of the disease. Promising results are derived from 
studies on abatacept and ustekinumab. The efficacy of JAK/STAT inhibitors in the 
management of GCA is currently under investigation.  
 









We strongly support the use of glucocorticoids as the initial therapy for the management 
of GCA [23]. We and others have observed that a prednisone dose of 40-60 mg/day 
prednisone yields rapid improvement of most clinical features of a GCA [55,56]. 
Glucocorticoids at this dose prevent from the development of visual loss in GCA. 
However, visual recovery is very rare and not expected, even if glucocorticoids are 
started rapidly, after the onset of visual loss. Therefore, it is far more preferable to treat 
GCA before visual loss occurs. In this regard, once prednisone is started, the 
development of new visual loss is very uncommon. 
We also agree with experts in the field on the limited effect of MTX and other 
conventional immunosuppressive drugs to reduce the cumulative glucocorticoid dose 
and induce prolonged remission of patients with GCA [22]. With respect to this, 
relapses are frequent when prednisone is tapered [17], and the efficacy of MTX for 
reduce relapses is often modest [57].  
From our point of view the GiACTA trial constituted a major step forward in the 
management of GCA. However, we do not use the anti-IL-6 receptor tocilizumab as a 
single therapy without glucocorticoids. Real life data from patients with GCA have also 
shown that this biologic agent is effective in the management of patients who are 
refractory to glucocorticoids and MTX [38]. Nevertheless, autopsy results have shown 
persistent vascular inflammation in patients who were apparently in clinical remission 
following tocilizumab therapy [58].  
Relapses are a major point of concern for clinicians who treat patients with GCA [17]. 
They are also common when tocilizumab is discontinued. The classic definition of 
relapse, considered to be present if a previously asymptomatic patients has again 
clinical features of GCA or PMR associated with an elevation of acute phase reactants, 









generally low in patients receiving this biologic agent. Therefore, it is possible that the 
requirement of increased acute phase reactants for the definition of relapse in patients 
included in the GiACTA trial may have overestimated the actual number of remissions, 
due to the favorable effect of tocilizumab to reduce CRP serum levels [40]. 
We feel that studies comparing the efficacy of tocilizumab versus MTX are required to 
confirm that this biologic agent may allow glucocorticoid discontinuation in a shorter 
period of time than the conventional immunosuppressive agents.  
Real-life studies to determine if the use of tocilizumab is truly associated with a 
reduction of side effects related to glucocorticoid therapy are also needed. 
An issue that needs to be addressed is to determine the profile of patient who may 
benefit of a specific therapy. For example, GCA patients presenting with very high 
inflammatory response may be susceptible to the use of tocilizumab whereas those with 
lower inflammation, often associated with higher risk of severe ischemic complications 
[59], could be treated with agents that reduce the effects of IFN-gamma, other 
inflammatory cytokine probably involved in the pathogenesis of this disease.   
We do not know if the JAK inhibitors, which have a broader effect on inflammatory 
pathways, may be more useful for the management of GCA than tocilizumab.  
Figure 1 shows a schematic view of the authors for a stepped treatment of GCA. 
 
3.1 Five-year view 
The identification of genetic or serological biomarkers will help us to better identify 
specific patterns of the disease, to disclose GCA patients at higher risk of severe 
ischemic complications such as visual loss. New biologic therapies will be used soon 
after the diagnosis of the disease in an attempt to induce early disease remission and 









inhibitors or perhaps interferon-ϒ antagonists for the management of patients with GCA 
looks promising, although more studies are still needed to draw conclusions of the 
efficacy of these agents.  
  
Article Highlights  
• IL-6 is a pivotal proinflammatory cytokine implicated in the pathogenesis of 
GCA.  
• Glucocorticoids are the mainstay of treatment in GCA.  
• Conventional immunosuppressive agents, such as MTX, are often used in 
relapsing GCA patients or as glucocorticoid sparing agents. However, its 
efficacy is often modest.  
• The anti-IL-6 receptor monoclonal antibody-tocilizumab has proved efficacy in 
patients with GCA to reduce relapses and the cumulative prednisone dose. 
• Tocilizumab is the only biologic agent currently approved for the management 
of GCA. 
• The use of other biologic agents and JAK inhibitors for the management of GCA 
is currently under investigation. 
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Figure 1. Schematic view of the authors for a stepped treatment of giant cell arteritis.  
Abbreviations: JAK/STAT: Janus kinase/signal transducers and activators of 
transcription; OP: osteoporosis. 
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